"Mycophenolic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.
| Descriptor ID |
D009173
|
| MeSH Number(s) |
D02.241.081.193.678 D10.251.618
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mycophenolic Acid".
Below are MeSH descriptors whose meaning is more specific than "Mycophenolic Acid".
This graph shows the total number of publications written about "Mycophenolic Acid" by people in this website by year, and whether "Mycophenolic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 3 | 0 | 3 |
| 2005 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mycophenolic Acid" by people in Profiles.
-
Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases. JCI Insight. 2024 Jun 04; 9(13).
-
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial. Lancet Rheumatol. 2024 Mar; 6(3):e168-e177.
-
Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2022 10 23; 10(1):150.
-
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 05 29; 397(10289):2070-2080.
-
Mycophenolate co-administration with quercetin via lipid-polymer hybrid nanoparticles for enhanced breast cancer management. Nanomedicine. 2020 02; 24:102147.
-
Elephantiasis nostras verrucosa secondary to scleroderma. Cutis. 2019 02; 103(2):E4-E6.
-
Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion. 2019 03; 59(3):921-926.
-
Metachronous Involvement, Diagnostic Imprecision of Serum Immunoglobulin G4 Levels, and Discordance Between Clinical and Radiological Findings in Immunoglobulin G4-Related Pachymeningitis: A Longitudinal Case Report. J Clin Rheumatol. 2017 Jun; 23(4):215-221.
-
Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep. 2011 Aug; 13(4):308-16.
-
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24; 353(21):2219-28.